secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009179
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154
-----------------------------------------------------------------

- Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.
- Cash and equivalents $19.7M at March 31, 2025, down from $21.6M at Dec 31, 2024.
- Initiated outpatient Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression; first patient dosing expected Q2 2025.
- Entered TLANDO license agreement for Brazil with Aché; exploring partnerships for LPCN 1154 and LPCN 2401.
- Plans proof-of-concept study for LPCN 2401 as adjunct to GLP-1 therapies, targeting elderly patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/0001641172-25-009179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer